P latelet secretion in response to agonist stimulation is a critically important step in both normal hemostasis and pathological arterial thrombosis. ADP release from dense granules is necessary to convert a low-grade, often reversible platelet activation event into an irreversible event, and targeting this pathway pharmacologically by inhibiting cyclooxygenase with aspirin or by directly inhibiting the P 2 Y 12 platelet ADP receptor with thienopyridine drugs is a cornerstone of arterial thromboprophylaxis. The frequent occurrence of bleeding complications with these commonly used therapies, however, speaks to the importance of this pathway in normal hemostasis. The role of α-granule secretion is less well understood, but studies during the past decade have increasingly pointed to biological and pathological importance. Patients with the rare congenital condition known as Gray Platelet Syndrome, in which α-granule biogenesis is defective, have a mild to moderate bleeding disorder, and mice genetically engineered to lack α-granules have prolonged thrombosis times in response to vascular injury in vivo and functional defects in platelet responses in vitro. 1 Discovery and characterization of the many proteins contained in α-granules or expressed on their membranes coupled with the use of elegant in vivo assays of thrombus formation in genetically manipulated mice have led to the hypothesis that the interaction of numerous ligands and receptors exposed in the platelet-platelet interspace after the initial events of platelet activation and aggregation, including ephrins, eph kinases, semaphorins, plexins, and gas6, is important in promoting thrombus growth and stability 2 and may be attractive targets for pharmacological intervention because normal hemostasis seems less affected by disruption of these pathways when compared with the ADP/P 2 Y 12 pathway.
See accompanying article on page 1187
In this issue of ATVB, an international team led by Kuijpers et al 3 from Maastricht add to this emerging story by showing a potentially important role for secreted thrombospondin-1, the most prevalent α-granule protein by mass, in thrombus formation. Using platelets from mice genetically deficient in thrombospondin-1 or its cognate receptor CD36, they found that initial buildup of platelet thrombi on collagen substrates was normal, but the thrombi were less stable and tended to dissolve spontaneously. Adding back platelet releasates from wild-type but not thrombospondin-1-deficient mice corrected the defect. These studies are consistent with previous reports that mice deficient in thrombospondin-1 or CD36 had prolonged thrombosis times in response to low-level arterial injury. Thrombospondin-1 is a large trimeric glycoprotein with multiple protein-protein interaction domains that can interact with numerous adhesive glycoproteins (including fibrinogen, fibronectin, collagen, and vonWillebrand factor), proteases, and cellular receptors, including CD36, CD47, and integrins. Thus, sorting out the exact mechanisms by which thrombospondin-1 promotes thrombosis is challenging. Isenberg et al 4 reported that thrombospondin-1 signaling through CD47 and CD36 promoted platelet activation by interfering with natural platelet inhibitory pathways mediated by cyclic nucleotides and nitric oxide. The study by Kuijpers et al 3 suggested that CD47 was not relevant in their system and pointed to a dominant role for CD36, which has been shown by our group and others to promote platelet activation directly by recruiting and activating an intracellular signaling complex made up of srcfamily kinases (fyn, lyn, and syk), MAP (mitogen activated protease) kinases (jnk1 and jnk2), and vav-family guanine nucleotide exchange factors. 5 CD36, unlike most of the other receptors implicated in postaggregation platelet signaling events, is densely expressed on the surface of resting platelets. It is a type B scavenger receptor that recognizes numerous danger-associated molecular patterns in addition to the so-called TSR (thrombospondin structural homology region) domain found in thrombospondin-1, thrombospondin-2, and numerous other proteins. Our group and others have shown that CD36 interaction with danger-associated molecular patterns, such as oxidized lowdensity lipoprotein, 6 advanced glycated proteins, 7 and cellderived microparticles, 8 generated during metabolic and inflammatory stress promotes platelet activation and in mouse models contributes to the prothrombotic state associated with hyperlipidemia, hyperglycemia, and oxidative vascular injury. Interestingly, CD36 expression levels vary widely in the human population and are correlated with platelet reactivity to danger-associated molecular patterns 9 ; CD36 genetic polymorphisms have been associated with fatal myocardial infarction in patients with known coronary disease.
Highly related to these observations are the recent studies from Wang et al 10 in Cleveland. They used a nonbiased platelet mRNA profiling strategy to discover that expression of the gene encoding the S100 calcium-modulated protein family member myeloid-related protein (MRP)-14 (also known as S100A9) was elevated in platelets from patients presenting with acute myocardial infarction. They followed up on this observation by reporting that MRP-8/MRP-14 heterodimers (S100A8/A9) are expressed in and secreted by platelets in response to agonists, and that deletion of the MRP-14 gene in mice markedly prolonged arterial thrombosis times in multiple vascular injury models. Infusion of wild-type platelets or purified MRP-14 into the MRP-14-deficient mice reversed the defect. Using mice deficient in CD36 showed that CD36 was required for MRP-14-dependent thrombosis.
Thus, CD36 can promote platelet activation and thrombus formation and stability by interacting with at least two endogenous ligands released from activated platelets in the microenvironment of a forming thrombus, as well as several endogenous danger-associated molecular patterns that circulate in plasma under pathological conditions. Individuals with inherited or acquired conditions associated with higher levels of CD36 or its ligands may be predisposed to acute arterial thrombotic events, whereas CD36 deficiency in humans is surprisingly common, occurring in ≤1% of individuals from Asian or African backgrounds; no reports have linked CD36 deficiency or genetic polymorphisms of thrombospondin-1 or MRP-14 with a bleeding diathesis. Perhaps the role of the platelet CD36 system in normal hemostasis is subtle enough to be compensated by other redundant system, or perhaps more likely the clinical phenotyping of subtle bleeding disorders was not robust enough to detect associations in published genome-wide studies. It is tempting to speculate that the hemostatic role of thrombospondin-1 and MRP-8/MRP-14 signaling via CD36 may have provided the evolutionary pressure that led to high levels of expression of this receptor on the platelet surface. In our modern world of diet-induced metabolic and inflammatory stress, this situation may not be advantageous, but targeting this prothrombotic pathway may have potential for treating or preventing atherothrombotic disorders.
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